Chronic Obstructive Pulmonary Disease as a Cardiovascular Diseases Risk Factor in Erbil

Authors

  • Goran Abubaker Osman Department of Nursing, College of Nursing, Hawler Medical University, Erbil, Iraq.
  • Halmat Authman Rasheed Department of Nursing, College of Nursing, Hawler Medical University, Erbil, Iraq.
  • Yousif Mohammed Younis Department of Nursing, College of Nursing, Hawler Medical University, Erbil, Iraq.
  • Newroz Khazi Aziz Department of Nursing, College of Nursing, Hawler Medical University, Erbil, Iraq.
  • Hemin Khlid Saber Department of Nursing, College of Nursing, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/ejnm.2019.12

Keywords:

Cardiovascular diseases, Chronic Obstructive Pulmonary Disease, Comorbidities

Abstract

Background and objectives: Chronic obstructive pulmonary disease (COPD) has been reported as the most common cause of morbidity and mortality all over the world. The present study aimed to investigate a possible link between chronic obstructive pulmonary dis-ease and increased risk of cardiovascular disease in Erbil, the Kurdistan Region of Iraq.
Methods: A quantitative, case-control study was conducted on 159 patients with COPD as the case group and 159 adult people without COPD as control group. Case groups were patients who have COPD and admitted to the medical ward at Hawler Teaching Hospital and Rzgary Teaching Hospital. Control groups were those without COPD and went to City Park and Mala-fandy Primary Health Center. Data was collected from January 2018 to August 2018 through direct interview and using a questionnaire. A spirometer machine was used to confirm the diagnosis of COPD. Data analysis was carried out through descriptive statistics (frequency and percentage), skeunosis-kurtosis test, t-test, Mann-Whitney U test, Pearson's Chi-squared test, and univariate logistic regression.
Results: Compared to the control group, patients with chronic obstructive pulmonary dis-ease were found to be at a significantly higher risk of developing hypertension, diabetes, ischemic heart disease, dyslipidemia, and lung cancer. Moreover, there was an inverse correlation between increased severity of chronic obstructive pulmonary disease and in-creased hypertension and stroke. In addition, chronic obstructive pulmonary disease, hypertension, diabetes, and dyslipidemia were found to be significant risk factors for ischemic heart disease.
Conclusions: The risk of cardiovascular comorbidities was significantly higher in the patients with chronic obstructive pulmonary disease and there is a significant association between chronic obstructive pulmonary disease and cardiovascular comorbidities.

Metrics

Metrics Loading ...

References

[1] de Lucas-Ramos P, Izquierdo-Alonso JL, Moro JM, Frances JF, Lozano PV, Bellón-Cano, JM., et al. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). International Journal of Chronic Obstructive Pulmonary Disease. 2012; 7:679.
[2] Sin DD, Man SP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proceedings of the American Thoracic Society. 2005; 2(1): 8-11.
[3] Sin DD, Man SP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003; 107(11):1514-1519.
[4] Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest Journal. 2005;128(4):2640–6.
[5] Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Euro-pean Respiratory Journal. 2009; 33(2):262–272.
[6] de Lucas-Ramos P, Izquierdo-Alonso JL, Moro JM, Bellón-Cano JM, Ancochea-Bermúdez J, Calle-Rubio M, Calvo-Corbella E, et al. Cardi-ovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study. Archivos de Bronconeumología ((English Edition)). 2008; 44(5):233-238.
[7] Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. International Journal of Chronic Obstructive Pulmonary Disease. 2009; 4: 337-349.
[8] Tanaka K, Senjyu H, Tawara Y, Tanaka T, Asai M, Tabusadani M, et al. Effects of Systematic Intervention for Chronic Obstructive Pulmonary Disease on Follow-up and Smoking Cessation Rates and Changes of the Pulmonary Function: A 7-year Longitudinal Study in a Japanese Rural City. Internal Medicine. 2018; 57(16): 2315-2323.
[9] Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. The Lancet Respiratory Medicine. 2015; 3(8): 631-639.
[10] Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, , Fabbri LM, Martinez FJ, Nishimura M, Stockley RA., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Ameri-can Journal of Respiratory and Critical Care Medicine. 2013;187(4):347-365.Johns DP, Walters JA, Walters EH. Diagnosis and early detection of COPD using spirometry. Journal of Thoracic Disease.2014; 6(11):1557.
[11] Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005; 127(6): 1952–1959.
[12] Mihalache A, Fitting JW, Nicod LP. Chronic obstructive pulmonary disease and its links with cardiovascular risk factors. Revue Medicale Suisse. 2015; 11 (495): 2151–2156, 2015.
[13] López Varela MV, Montes de Oca M, Halbert R.PLATINO team. Comorbidities and health status in individuals with and without COPD in five Latin American cities: the PLATINO study. Arch Bronconeumol. 2013; 49 (11): 468-474
[14] Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society. 2008;5(4):549-55.
[15] Imaizumi Y, Eguchi K, Kario K. Lung Disease and Hypertension. Pulse (Basel). 2015;2(1-4):103-12.
[16] Shujaat A, Minkin R, Eden E. Pulmonary hypertension and chronic corpulmonale in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2007;2(3):273-82.
[17] Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World Journal of Diabetes. 2015;6(13):1246-58.
[18] Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Canadian Journal of Cardiol. 2018; 34(5):575-584.
[19] Lazaro P, Murga N, Aguilar D, Hernandez-Presa MA: Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. The inertia study. Revista Espanola de Cardiologia. 2010; 63: 1428-1437.
[20] Ho TW, Huang CT, Ruan SY, Tsai YJ, Lai F, Yu CJ. Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality. PLoS One. 2017;12(4):e0175794. Published 2017 Apr 14. doi:10.1371/journal.pone.0175794
[21] Takahashi T, Yoshihisa A, Sugimoto K. Associations between diabetes mellitus and pulmonary hypertension in chronic respiratory disease patients. PLoS One. 2018;13(10):e0205008. Published 2018 Oct 9. doi:10.1371/journal.pone.0205008.

Downloads

Published

2019-11-30

How to Cite

1.
Osman GA, Rasheed HA, Younis YM, Aziz NK, Saber HK. Chronic Obstructive Pulmonary Disease as a Cardiovascular Diseases Risk Factor in Erbil. Erbil j. nurs. midwifery [Internet]. 2019 Nov. 30 [cited 2024 Apr. 18];2(2):93-100. Available from: https://ejnm.hmu.edu.krd/index.php/ejnm/article/view/75

Issue

Section

Original Articles